about
Applications of CYP450 testing in the clinical settingOxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenaseInvestigating the Role of Plasma Glucose Concentration as a Phenotypic Marker for CYP2C9 Genetic Variants, in the Diabetic Population of GujaratCYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases.Drug resistance is conferred on the model yeast Saccharomyces cerevisiae by expression of full-length melanoma-associated human ATP-binding cassette transporter ABCB5.Pharmacogenomics: the genetics of variable drug responses.Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes.The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrelCloning of cytochrome P-450 2C9 cDNA from human liver and its expression in CHL cells.ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates.Effect of Red Ginseng on cytochrome P450 and P-glycoprotein activities in healthy volunteersEffect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach.Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats.Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans.Influence of losartan on the hypoglycemic activity of glimepiride in normal and diabetic rats.Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity.Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray.SuperDRUG2: a one stop resource for approved/marketed drugs.Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.Effects of polymorphic variation on the thermostability of heterogenous populations of CYP3A4 and CYP2C9 enzymes in solution
P2860
Q24621760-899E15E2-D8C8-478F-BC09-1CC3679DF852Q24682914-4D9C66D4-9027-41A1-AB42-CBCB2E0B1486Q33555327-FF4172A3-D9B1-4A24-9899-64A431BE4250Q33984240-6E00847B-E394-4C57-8236-D82EF1A96DA7Q34293596-47898BDE-F1D0-46AD-AA4F-D499E11FACEEQ34976915-9E9F9926-91D4-4604-93E6-5F9B222C971BQ35718630-13AE83A0-FF3F-46D8-B73E-09E0FB11642AQ35803966-221F4D59-6BF3-4945-B3E8-F136ED227D1FQ35827129-0CFEE24D-BD20-4B87-9C1E-F22FDD6C4769Q36316100-93B99DE0-DC25-4717-9CAC-FEDEC20029D6Q36949532-987C983C-34F4-4C75-9EB8-01BCFC64AF84Q37314453-25C2CA89-FCD0-45D2-8D19-E91CA73A1C93Q37399585-CED963DF-E398-406E-844D-CDA75D95851AQ37729496-BD4BF614-53E9-47B4-A13F-F209111D1D10Q42284291-678C50BD-239D-4287-AAEA-A5F15C4F34D9Q42685320-C035973F-6E90-4A95-89E1-5CF57EA85BD1Q42780160-7465E4DB-5C2A-447B-8039-F4DD949FD0ECQ43211983-A0FDC9FB-C635-4103-B4AD-820DE58FAD3CQ47142191-95BC82D6-93C3-4937-865C-65ABF5BEB6F9Q47570862-F973E842-BD11-4C64-B5B5-C7D14A12FA32Q58796074-C92E9D35-DF9B-4315-95C4-AC71DD6D8003
P2860
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Role of CYP2C9 polymorphism in losartan oxidation.
@en
Role of CYP2C9 polymorphism in losartan oxidation.
@nl
type
label
Role of CYP2C9 polymorphism in losartan oxidation.
@en
Role of CYP2C9 polymorphism in losartan oxidation.
@nl
prefLabel
Role of CYP2C9 polymorphism in losartan oxidation.
@en
Role of CYP2C9 polymorphism in losartan oxidation.
@nl
P2093
P1476
Role of CYP2C9 polymorphism in losartan oxidation.
@en
P2093
P304
P577
2001-07-01T00:00:00Z